AMA Rejects Permanent CPT Code for IceCure's Breast Cryoablation — Reimbursement Stays Temporary
ICCM is trading near its 52-week low of $1.55 (3.2% above the low) on elevated volume (2.5× avg).
Summary
AMA declined to grant a permanent CPT Category I code for IceCure's breast cryoablation, keeping reimbursement on a temporary Category III code. The company may resubmit in June 2027.
Key Events · Product Development and Regulatory · ICCM
-
AMA Rejects Permanent CPT Code
The AMA CPT Editorial Panel declined IceCure's request to transition cryoablation for breast tumors from a temporary Category III code to a permanent Category I code, calling the move premature.
-
Reimbursement Impact Limited Near-Term
The existing Category III code remains in place, allowing facilities to bill CMS approximately $4,000 per ProSense procedure, so current commercial activities are unaffected.
-
Resubmission Window June 2027
IceCure plans to expand clinical evidence and utilization before potentially resubmitting the CPT Category I code request in June 2027.
-
Going-Concern Backdrop
The setback comes after IceCure warned in August that its $12M cash position is insufficient to fund operations, making faster commercial adoption critical.
Analysis · ICCM · Industrial Applications And Services
The AMA's CPT Editorial Panel declined IceCure's request to upgrade cryoablation for breast tumors from a temporary Category III code to a permanent Category I code, calling the transition premature. The existing Category III code remains in place, so facilities can still bill CMS roughly $4,000 per ProSense procedure — meaning near-term revenue is not directly hit. But the rejection delays a key reimbursement milestone that would have made the procedure more attractive to hospitals and payers, and the company must now wait until June 2027 to resubmit. For a company trading near its 52-week low with a going-concern warning and only $12M in cash as of August, any setback to commercial adoption matters.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICCM was trading at $1.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $1.55 to $42.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.